|
SSFA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73949999959788E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.09730000000952E-05 |
| Normal-vs-Stage2 |
1.750260E-04 |
| Normal-vs-Stage3 |
5.17209997052959E-09 |
| Normal-vs-Stage4 |
9.82725012477204E-12 |
| Stage1-vs-Stage2 |
4.560200E-01 |
| Stage1-vs-Stage3 |
1.248320E-02 |
| Stage1-vs-Stage4 |
3.73580000001539E-06 |
| Stage2-vs-Stage3 |
2.983600E-01 |
| Stage2-vs-Stage4 |
1.585800E-02 |
| Stage3-vs-Stage4 |
6.684200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.39520000009119E-07 |
| Normal-vs-AfricanAmerican |
1.976600E-03 |
| Normal-vs-Asian |
7.573000E-04 |
| Caucasian-vs-AfricanAmerican |
9.811400E-01 |
| Caucasian-vs-Asian |
7.241000E-01 |
| AfricanAmerican-vs-Asian |
8.445400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.23900000004173E-06 |
| Normal-vs-Female |
3.95060000046854E-07 |
| Male-vs-Female |
6.105600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.603600E-04 |
| Normal-vs-Age(41-60Yrs) |
4.77579999991207E-07 |
| Normal-vs-Age(61-80Yrs) |
8.06929967289705E-10 |
| Normal-vs-Age(81-100Yrs) |
2.322800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.963600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.261300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.451400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.264410E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.112200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.032200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.019600E-02 |
| Classical-VS-Follicular |
1.437150E-01 |
| Classical-VS-Other |
6.547400E-01 |
| Classical-VS-Normal |
1.66164999999552E-05 |
| Tall-VS-Follicular |
4.038400E-01 |
| Tall-VS-Other |
3.642800E-01 |
| Tall-VS-Normal |
1.39300000001619E-06 |
| Follicular-VS-Other |
4.047200E-01 |
| Follicular-VS-Normal |
3.28969999996431E-06 |
| Other-VS-Normal |
2.014800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.81129999998753E-07 |
| Normal-vs-N1 |
1.64059999996358E-06 |
| N0-vs-N1 |
4.341800E-01 |
|
|
